Core Insights - Guangzhou Pharmaceutical Group Co., Ltd. (referred to as "Guangyao Group") has established a joint venture named Guangzhou Baiyunshan (600332) Xihe Health Pharmaceutical Co., Ltd. (referred to as "Baiyunshan Xihe Health") with the Xiamen Rare Earth Research Institute to enter the nuclear medicine sector [1][2] - Nuclear medicine, which involves radioactive drugs for diagnosis and treatment, is becoming a strategic focus for the global biopharmaceutical industry, with major pharmaceutical companies investing in this area [1] - The Chinese government has introduced policies to support the development of the nuclear medicine industry, including the "Medical Isotope Medium and Long-term Development Plan (2021-2035)" [1] Company Developments - Baiyunshan Xihe Health was established on August 15 with a registered capital of 50 million yuan, co-funded by Guangyao Group and the Xiamen Rare Earth Research Institute [2] - The technical team of Baiyunshan Xihe Health successfully produced high-quality Zirconium-89 using an advanced domestic solid target system, filling a gap in domestic production [2] - Guangyao Group has set clear goals: short-term focus on rapid industrialization of rare earth diagnostic and therapeutic nuclear products; mid-term plans to build a nuclear production and R&D base; and long-term commitment to providing smart nuclear medical solutions [2]

Group 1 - The Hunan China Nuclear Tumor Hospital (Phase I) project has officially topped out on June 14, 2023, with an expected completion and opening in 2026 [1] - The project covers a total construction area of approximately 330,000 square meters, with a planned capacity of 1,800 beds (917 beds for Phase I) and a total investment exceeding 3 billion yuan [3] - The hospital is positioned as a nuclear medical center and flagship oncology specialty hospital in Central and Southern China, equipped with advanced medical technologies such as proton heavy ion therapy systems and BNCT systems [3] Group 2 - The project is a result of a strategic cooperation agreement signed in 2017 between China National Nuclear Corporation (CNNC) and the Hunan Provincial Government, aimed at establishing the CNNC Hunan Proton Medical Center [4] - CNNC Health, as a professional platform for nuclear medical industry investment and management, is collaborating with local government to implement the "Healthy China" strategy and ensure the project is included as a key provincial and municipal engineering project [4] - The hospital aims to integrate various resources in the Yuhua District to activate a "nuclear medical innovation ecosystem," focusing on tumor diagnosis and driving the development of nuclear drug research, nuclear medical equipment manufacturing, and talent cultivation [6]